Graham Lieschke M.B., B.S., B.Med.Sc., Ph.D., F.R.A.C.P.
Australian Regenerative Medicine Institute, and Royal Melbourne Hospital, Australia
Scientific expertise: Haematopoiesis – benign and malignant, infectious disease, innate immunity, clinical care/medicine
Graham Lieschke is an Australian clinician/scientist. His current appointments are as Clinical Haematologist at the Royal Melbourne Hospital, and as Professorial Fellow / NHMRC Senior Research Fellow at the Australian Regenerative Medicine Institute at Monash University in Melbourne. Since 1997, his research laboratory has been at the forefront of using zebrafish models to understand white blood cell development, function and disease. Current projects use zebrafish models to study the transcriptional regulation of myeloid development and diseases involving leukocytes such as inflammation, infection and leukemia. Prof Lieschke has held fellowships from the Cancer Council of Victoria, Howard Hughes Medicial Institute, Wellcome Trust and NHMRC and significant research funding from NIH and NHMRC. He has held multiple leadership roles in the international zebrafish research and hematology communities. He is also an accomplished organist and conductor, specializing in the music of JS Bach.
David Langenau, Ph.D.
Massachusetts General Hospital, USA
Scientific expertise: Cancer and Stem Cells
David Langenau is the Director of Molecular Pathology at the Massachusetts General Hospital in Boston, MA. He is an Associate Professor of Pathology at Harvard Medical School and Principal Investigator at the Harvard Stem Cell Institute. His research focuses on uncovering mechanisms that drive progression and relapse in pediatric tumors. Using novel, transgenic zebrafish models of pediatric sarcoma and leukemia that mimic human malignancy, his group has undertaken studies to discover novel therapies by addition of drugs to the water and imaging tumor growth in live zebrafish. Moreover, his group has utilized detailed imaging studies to visualize tumor cells in live animals and assess how cellular heterogeneity drives continued tumor growth. Capitalizing on insights gained from our zebrafish models of cancer, his findings are commonly extended to human disease.
Vice President in waiting
Richard White MD, PH.D.
Memorial Sloan Kettering Cancer Center
James Amatruda MD, PH.D.
UT Southwestern Medical Center
Liz Patton PH.D., MRC
MRC Human Genetics Unit, University of Edinburgh, UK